@article{dcd6e8e3f8b54e8a944edbebbb57f202,
title = "Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al",
author = "Andreas Greinacher and Florian Langer and Mike Makris and Menaka Pai and Sue Pavord and Huyen Tran and Warkentin, \{Theodore E.\}",
note = "Funding Information: F. Langer has received personal fees for lectures, advisory boards, or consultancy and/or research support from Aspen, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, CSL Behring, Daiichi Sankyo, LEO Pharma, Mitsubishi Tanabe Pharma, Octapharma, Pfizer, Sanofi, Viatris, and Werfen, outside the submitted work. H. Tran has received honoraria for advisory board participations, research support, or educational lectures from Bayer, CSL Behring, Novo Nordisk, Pfizer, Roche, and Sanofi outside the submitted work. M. Makris is the project lead for the European Haemophilia Safety Surveillance System (EUHASS), which received funding from Bayer, Biomarin, BPL, CSL Behring, Kedrion, NovoNordisk, Octapharma, Pfizer, Roche, Sanofi, Sobi, and Takeda. M. Pai has received honoraria for a lecture from Novartis, and has provided expert witness testimony relating to thrombotic disorders. S. Pavord has received honoraria for educational lectures, chairing and participation in advisory boards or sponsorship for running courses, from SOBI, Amgen, Alexion, Sanofi, CSL Behring, Novartis, Pharmacosmos, and Vifor Pharma, outside the submitted work. T. E. Warkentin has received lecture honoraria from Alexion and Instrumentation Laboratory, and royalties from Informa (Taylor \& Francis); has provided consulting services to Aspen Canada, Aspen Global, Bayer, CSL Behring, Ergomed, and Octapharma; has received research funding from Instrumentation Laboratory; and has provided expert witness testimony relating to heparin‐induced thrombocytopenia (HIT) and non‐HIT thrombocytopenic and coagulopathic disorders. A. Greinacher reports grants and nonfinancial support from Aspen, Boehringer Ingelheim, MSD, Bristol Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc., Rovi, Sagent, and Biomarin/Prosensa, personal fees from Aspen, Boehringer Ingelheim, MSD, Macopharma, BMS, Chromatec, and Instrumentation Laboratory, and nonfinancial support from Boehringer Ingelheim, Portola, Ergomed, GTH e.V. outside the submitted work. ",
year = "2022",
month = feb,
doi = "10.1111/jth.15619",
language = "English",
volume = "20",
pages = "542--543",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "2",
}
SDG 3 Good Health and Well-being